Irish Dairy Industry Sees Surge in Whey Protein Demand Due to GLP-1 Drugs

The Irish dairy industry has witnessed a notable increase in demand for whey protein, largely attributed to the rising use of GLP-1 weight-loss medications such as Ozempic, Wegovy, and Mounjaro. These drugs, produced by companies like Novo Nordisk and Eli Lilly, are leading to increased protein consumption among users to counteract muscle mass loss during weight loss.

Carbery Group, a prominent player in the dairy and nutrition sector, reported operating profits of €52.3 million with revenues climbing 8% to €723 million in 2025. The company noted a substantial rise in whey protein demand, particularly in the US, where GLP-1 drugs are gaining popularity. Jason Hawkins, Carbery's CEO, highlighted the dual benefit of increased demand for both nutrition and flavor products.

Meanwhile, Tirlán is investing €126 million at its Ballyragget site to enhance its whey protein production capabilities. This expansion aims to position Tirlán as a leader in global nutritional protein innovation, with the facility expected to be operational by mid-2027.

Conor Mulvihill of Dairy Industry Ireland emphasized Ireland's competitive edge in whey production, citing the quality of products sourced fr om grass-fed cows. He noted that Ireland's success in whey mirrors its achievements in the infant formula sector, wh ere the country produces 10% of the world's supply.

The impact of GLP-1 drugs extends beyond Ireland, affecting food industries globally. Companies like Hershey have reported increases in protein bar consumption, while others like Magnum Ice Cream Co. are facing challenges due to shifts in consumer spending.